Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Supplementary Material for: Leveraging NLP for Psychiatric Phenotyping from Spanish EHR: Enabling the Investigation of Transdiagnostic Symptom Profiles at Scale by figshare admin karger (2628495)

“…The COMBINED algorithm improved overall recall, without significantly decreasing precision (F1 of 0.78 and 0.77 on HOMO and CSJDM, respectively). …”

Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Supporting Data for "Managing NPO-Funder Relations for Financial Sustainability: Insights from Social Service Nonprofits in China" by Shiqi Peng (11134716)

“…Results found that greater reliance on a dominant funder was significantly associated with lower revenue generation (β = -0.5, p < 0.05), reduced surplus retention (β =-0.7, p < 0.001), and decreased operational efficiency (β = -0.0, p < 0.001). …”

Data Sheet 1_Strategies for enhancing yield and quality of forage-grain dual-purpose ratoon rice: role of first-season density and nitrogen management.docx by Yuyuan Ouyang (15350374)

“…Results showed that: Silage yield increased significantly with higher density and nitrogen input. …”

Data Sheet 2_The characteristics of auditorial event-related potential under propofol sedation associated with preoperative cognitive performance in glioma patients.docx by Xinxin Wang (134010)

“…Compared to that in the non-MCI group, the average amplitude of the MMN component evoked by the novel stimulus significantly decreased during the recovery period in the MCI group (−3.895 ± 1.961 μV vs. -1.617 ± 1.831 μV, p = 0.003). …”

Data Sheet 1_The characteristics of auditorial event-related potential under propofol sedation associated with preoperative cognitive performance in glioma patients.docx by Xinxin Wang (134010)

“…Compared to that in the non-MCI group, the average amplitude of the MMN component evoked by the novel stimulus significantly decreased during the recovery period in the MCI group (−3.895 ± 1.961 μV vs. -1.617 ± 1.831 μV, p = 0.003). …”

Table 1_The characteristics of auditorial event-related potential under propofol sedation associated with preoperative cognitive performance in glioma patients.docx by Xinxin Wang (134010)

“…Compared to that in the non-MCI group, the average amplitude of the MMN component evoked by the novel stimulus significantly decreased during the recovery period in the MCI group (−3.895 ± 1.961 μV vs. -1.617 ± 1.831 μV, p = 0.003). …”

Data Sheet 3_The characteristics of auditorial event-related potential under propofol sedation associated with preoperative cognitive performance in glioma patients.docx by Xinxin Wang (134010)

“…Compared to that in the non-MCI group, the average amplitude of the MMN component evoked by the novel stimulus significantly decreased during the recovery period in the MCI group (−3.895 ± 1.961 μV vs. -1.617 ± 1.831 μV, p = 0.003). …”